| pubmed-article:15035651 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15035651 | lifeskim:mentions | umls-concept:C0012634 | lld:lifeskim |
| pubmed-article:15035651 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:15035651 | lifeskim:mentions | umls-concept:C0027819 | lld:lifeskim |
| pubmed-article:15035651 | lifeskim:mentions | umls-concept:C0015450 | lld:lifeskim |
| pubmed-article:15035651 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:15035651 | pubmed:dateCreated | 2004-3-23 | lld:pubmed |
| pubmed-article:15035651 | pubmed:abstractText | Neuroblastoma is the most common extra-cranial solid tumor in children and has a heterogeneous clinical presentation and course. Clinical and biologic features of this disease have been used to develop risk-based therapy. Patients with low-risk disease can be treated with surgery alone. Patients with intermediate-risk features have an excellent prognosis after treatment with surgery and a relatively short course of standard dose chemotherapy. Unfortunately, most children with neuroblastoma present with advanced disease. More than 60% of patients with high-risk features will succumb to their disease despite intensive therapy including a myeloablative consolidation. Research efforts to understand the biologic basis of neuroblastoma and to identify new, more effective therapies are essential to improve the outcome for these children. | lld:pubmed |
| pubmed-article:15035651 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15035651 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15035651 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15035651 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15035651 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15035651 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15035651 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15035651 | pubmed:issn | 1174-5878 | lld:pubmed |
| pubmed-article:15035651 | pubmed:author | pubmed-author:MatthayKather... | lld:pubmed |
| pubmed-article:15035651 | pubmed:author | pubmed-author:GoldsbyRobert... | lld:pubmed |
| pubmed-article:15035651 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15035651 | pubmed:volume | 6 | lld:pubmed |
| pubmed-article:15035651 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15035651 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15035651 | pubmed:pagination | 107-22 | lld:pubmed |
| pubmed-article:15035651 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:15035651 | pubmed:meshHeading | pubmed-meshheading:15035651... | lld:pubmed |
| pubmed-article:15035651 | pubmed:meshHeading | pubmed-meshheading:15035651... | lld:pubmed |
| pubmed-article:15035651 | pubmed:meshHeading | pubmed-meshheading:15035651... | lld:pubmed |
| pubmed-article:15035651 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15035651 | pubmed:articleTitle | Neuroblastoma: evolving therapies for a disease with many faces. | lld:pubmed |
| pubmed-article:15035651 | pubmed:affiliation | Division of Pediatric Hematology/Oncology, University of California, San Francisco 94143-0106, USA. | lld:pubmed |
| pubmed-article:15035651 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15035651 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:15035651 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:15035651 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15035651 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15035651 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15035651 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15035651 | lld:pubmed |
